Retatrutide vs Survodutide

Overview

Retatrutide and survodutide represent two different multi-agonist approaches to obesity treatment. Retatrutide is Eli Lilly’s triple agonist (GLP-1/GIP/glucagon), while survodutide is Boehringer Ingelheim’s dual agonist (GLP-1/glucagon). Both include glucagon agonism but differ in GIP activity.

Mechanism Comparison

Aspect	Retatrutide	Survodutide
GLP-1 Activity	Yes	Yes
GIP Activity	Yes	No
Glucagon Activity	Yes	Yes
Total Targets	3	2
Closest Comparator	Tirzepatide + glucagon	Oxyntomodulin-like

Why GIP Matters

The difference between these drugs centers on GIP:

Retatrutide (with GIP):

• GIP enhances insulin secretion
• GIP may contribute to weight loss via central effects
• Proven concept from tirzepatide success

Survodutide (without GIP):

• Simpler dual mechanism
• Avoids potential GIP-related effects
• Focus on glucagon’s liver benefits

Evidence Comparison

Aspect	Retatrutide	Survodutide
Development Phase	Phase 3	Phase 3
Key Trial	TRIUMPH program	Multiple Phase 2/3
MASH Focus	Yes	Primary focus
Obesity Focus	Yes	Yes

Weight Loss Comparison

Retatrutide (Phase 2)

Dose	Weight Loss (48 weeks)
8mg	~22%
12mg	~24%

Survodutide (Phase 2)

Dose	Weight Loss (46 weeks)
4.8mg	~18-19%

Note: Different trial designs; direct comparison not possible.

MASH/NASH Data

Both compounds show effects on liver disease:

Outcome	Retatrutide	Survodutide
MASH Resolution	Being studied	Up to 83% (Phase 2)
Liver Fat Reduction	Significant	Significant
Fibrosis Improvement	Data pending	Demonstrated
Primary Indication	Obesity (MASH secondary)	MASH (primary focus)

Survodutide has more advanced MASH-specific development.

Regulatory Status

Aspect	Retatrutide	Survodutide
FDA Status	Investigational	Investigational
Phase 3 Programs	TRIUMPH (obesity, T2D)	MASH, Obesity
Developer	Eli Lilly	Boehringer Ingelheim
Expected Approval	2026+	2025-2026

Side Effect Profile

Effect	Retatrutide	Survodutide
Nausea	Common (dose-dependent)	Common
Vomiting	Common	Common
Diarrhea	Common	Common
Dose-limiting GI	Higher doses affected	Present

Triple agonism may increase GI burden, but titration helps manage.

Administration

Aspect	Retatrutide	Survodutide
Route	Subcutaneous	Subcutaneous

Key Differences

Factor	Retatrutide	Survodutide
GIP Activity	Yes	No
Weight Loss	~24% (highest dose)	~18-19%
MASH Focus	Secondary	Primary
Complexity	Triple agonist	Dual agonist
Developer	Eli Lilly	Boehringer Ingelheim

Strategic Positioning

Retatrutide

• Positioned as maximum-efficacy obesity treatment
• Builds on tirzepatide success (adds glucagon)
• Lilly’s next-generation blockbuster

Survodutide

• Positioned for MASH indication
• Glucagon focus for liver benefits
• First-in-class for MASH if approved

Summary

• Retatrutide is a triple agonist showing ~24% weight loss - potentially best-in-class for obesity
• Survodutide is a dual agonist with strong MASH data and ~18% weight loss
• Both include glucagon agonism for enhanced metabolic effects
• GIP presence distinguishes mechanisms and possibly efficacy ceiling
• Different regulatory strategies: obesity vs MASH first-in-class

---

This comparison is for educational purposes only. Both compounds are investigational and not approved. Consult a healthcare provider for treatment decisions.